Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

• Confirmed diagnosis of hepatocellular carcinoma
• Surgical evaluation by a member of the Liver Tumor Program must conclude the patient is not a candidate for resection or ablation
• Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0-2
• Able to comprehend and provide written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria:

• Absolute granulocyte count =\<1,500/ul
• Platelet count =\<75,000/ul
• Serum creatinine >= 2.0 mg/dl

• Serum bilirubin

  • >= 2.0 mg/dl for bilateral treatment or lobar treatment
  • >= 3.0 mg/dl for single lesion which could be treated by segmental fusion
• History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine
• Bleeding, diathesis not correctable by usual forms of therapy
• Severe peripheral vascular disease that would preclude catheterization
• Portal hypertension with portal venous shunt away from the liver

• Evidence of potential delivery greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:

  1. first TheraSphere administration; or
  2. cumulative delivery of radiation to the lungs > 30 Gy over multiple treatments
• Evidence of any detectable Tc-99m MMA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow
• Significant extrahepatic disease representing an imminent life-threatening outcome
• Severe liver dysfunction (Childs' Classification C) or pulmonary insufficiency (requiring continuous oxygen therapy)
• Active uncontrolled infection
• Significant underlying medical or psychiatric illness
• Pregnant women may not participate
• Children may not participate